Lung Cancer/Thoracic Malignancies Science Highlights
This session highlights six of the most clinically relevant abstracts within the Lung Cancer/Thoracic Malignancies track of the 2022 ASTRO Annual Meeting Scientific Program. These noteworthy scientific abstracts share important findings and feature cutting edge research from leaders in the field. The Discussant compares and contrasts the current data to help you digest the latest science; places the study into context; and describes how the study can be put into clinical practice, if recommended.
- Pembrolizumab plus Concurrent Chemoradiation Therapy (cCRT) for Unresectable, Locally Advanced, Stage III NSCLC: KEYNOTE-799 2-Year Update
- iSABR: Safety and Efficacy Results from a Phase II Study of SABR in Combination with Durvalumab for Early-Stage Medically Inoperable NSCLC
- Comparison of Simultaneous Integrated Boost IMRT for Dose Escalation (54 Gy) and Conventional IMRT (45 Gy) Twice Daily Combined With Concurrent Chemotherapy for Limited-Stage Small-Cell Lung Cancer: Analysis of Two Prospective Trials
- Left Anterior Descending Coronary Artery Radiation Dose Association with All-Cause Mortality in NRG Oncology Trial RTOG 0617
- Association of Cardiac Sub-Structure Radiation Dose with Bradyarrhythmias and Tachyarrhythmias after Lung Cancer Radiotherapy
- Validation of the Prognostic Utility of ESTRO/EORTC Oligometastatic Disease Classification: A Secondary Analysis from the Population-Based Phase II SABR-5 Trial
This activity is available from February 28, 2023, through 11:59 p.m. Eastern time on December 31, 2023.
This activity was originally recorded at ASTRO’s Annual Meeting on October 26, 2022.
The activity is designed to meet the interests of radiation oncologists, radiation oncology residents, physicists and radiation dosimetrists.
Upon completion of this activity, participants:
- Have had the opportunity to increase their level of knowledge, as required to improve competency and performance in the field of oncology.
- When appropriate, implement the advances in radiation oncology that help improve patient outcomes and quality of life.
Discussant: Inga S. Grills, MD, Department of Radiation Oncology, Beaumont Health
The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 0.50 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 0.50 Certificate of AttendanceThis activity was designated for 0.50 AMA PRA Category 1 Credit™.
ASTRO members must log in to the ASTRO website to view and receive the free member rate.
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.
Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.
The course and its materials will only be available on the ASTRO website until December 31, 2023, regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.